1.	Phase III Study of IDEC-Y2B8 in Patients With Progressive Follicular B-Cell Non-Hodgkin's Lymphoma That is Refractory to Prior Rituximab Therapy Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: IDEC-106-06, MAYO-987804, UCLA-9808026
2.	Phase I/II Study of CpG 7909, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Patients With CD20+ Recurrent or Refractory Non-Hodgkin's Lymphoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Diagnostic, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: MAYO-LS0382, MAYO-IRB-703-04, NCT00438880
3.	Phase II Study of Ibritumomab Tiuxetan (IDEC-Y2B8) Radioimmunotherapy in Patients with Relapsed or Refractory, Low Grade or B-Cell, Non-Hodgkin's Lymphoma and Mild Thrombocytopenia Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-9804024, IDEC-106-05, NCI-G99-1614
4.	Phase II Study of Rituximab and Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Relapsed or Refractory, Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UAB-9930, GUMC-00095, IDEC-106-98, NCI-G00-1731, NCT00005592
5.	Phase II Study of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Patients Age 60 and Over With Previously Untreated Diffuse Large B-Cell Lymphoma Phase: Phase II Type: Supportive care, Treatment Status: Closed Age: 60 and over Sponsor: NCI Protocol IDs: MSKCC-02090, NCT00058422
6.	Phase I Study of Rituximab Followed By Yttrium Y 90 Ibritumomab Tiuxetan With or Without Autologous Peripheral Blood Stem Cell Transplantation in Children With Recurrent or Refractory CD20-Positive Lymphoma Phase: Phase I Type: Treatment Status: Completed Age: Under 22 Sponsor: NCI Protocol IDs: COG-ADVL0013, NCT00036855, ADVL0013